Trial Profile

A Randomised, Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570 Administered in Subjects With Overweight or Obesity

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 30 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Mar 2025 Status changed from recruiting to discontinued. Reason the study was stopped: Decision by Sponsor, LSLV is planned for 21-Mar-2025.
09 Sep 2024 According to a Zealand Pharma media release, company will present further details from Part 1 and Part 2 of this Phase 1b trial at a future scientific congress.
09 Sep 2024 According to a Zealand Pharma media release, company are now evaluating potential use of higher doses of dapiglutide up to 26 mg over a longer treatment duration of 28 weeks in Part 2 of this ongoing trial and company anticipates topline results in the first half of 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com